Results 101 to 110 of about 136,428 (330)
Animal Models and Experimental Medicine, EarlyView.The current study characterized temporal changes in glomerular gene expression, pathology, and biomarkers in a mouse model of hypertension‐accelerated diabetic kidney disease (DKD). Progressive albuminuria and glomerulosclerosis were paralleled by dynamic transcriptomic changes associated withmetabolic dysfunction, extracellular matrix remodeling, and ...
Adam B. Marstrand‐Jørgensen +8 more
wiley +1 more source
Ibn Al-Haitham Journal for Pure and Applied Sciences, 2017 The glucagon-like peptide-1 is secreted by intestinal L cells in response to nutrient ingestion. It regulates the secretion and sensitivity of insulin while suppressing glucagon secretion and decreasing postprandial glucose levels , additionally ...
Ahmed A. Lazim, Muntaha A. Lafta
doaj
GLP-1 and Its Role in Glycogen Production: A Narrative Review
BiomedicinesGlucagon-like peptide-1 (GLP-1) has emerged as a pivotal regulator in the management of glucose homeostasis, glycogen metabolism, and energy balance, positioning it as a critical therapeutic target for addressing obesity, metabolic syndrome, and type 2 ...
Joseph Lotosky +8 more
doaj +1 more source
Cardiovascular Effects of Glucagon-Like Peptide 1
Mini-Reviews in Medicinal Chemistry, 2011 Glucagon-like peptide-1 (GLP-1) is involved in satiety control and glucose homeostasis. Besides, GLP-1 has cardiovascular effects. In experimental models, GLP-1 increases cardiac output and exerts a direct vasodilatory effect. In animals with dilated cardiomyopathy GLP-1 improves left ventricular performance.
Papazafiropoulou, A. +3 more
openaire +3 more sources
Advanced NanoBiomed Research, EarlyView.This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari +5 more
wiley +1 more source
Journal of Pharmaceutical Policy and PracticeBackground High prices and other access barriers have contributed to the rise of a market for compounded glucagon-like peptide-1 receptor agonists for weight loss in the United States. This market has not been systematically studied. We conducted a pilot
Michael J. DiStefano +4 more
doaj +1 more source
Hepatocyte-specific HIF-1α ablation improves obesity-induced glucose intolerance by reducing first-pass GLP-1 degradation. [PDF]
, 2019 The decrease in incretin effects is an important etiologic component of type 2 diabetes with unknown mechanisms. In an attempt to understand obesity-induced changes in liver oxygen homeostasis, we found that liver HIF-1α expression was increased mainly ...
Bandyopadhyay, Guatam K +3 more
core
Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans [PDF]
, 2006 Background: Exogenous use of the intestinal hormone glucagon-like peptide 1 (GLP-1) lowers glycaemia by stimulation of insulin, inhibition of glucagon, and delay of gastric emptying.Aims: To assess the effects of endogenous GLP-1 on endocrine pancreatic ...
Göke, Burkhard +6 more
core +2 more sources
Arthritis &Rheumatology, Accepted Article.Objective GLP‐1 receptor agonists (GLP‐1RAs) and SGLT2 inhibitors (SGLT2is) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP‐1RAs, or SGLT2is, vs.
Derin Karacabeyli +4 more
wiley +1 more source